Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.

Gino Avellone, Antonio Pinto, Di Nicola, Vitacolonna, Di Febbo, Falco, Ballone, Ciabattoni, Salvati, Davì

Risultato della ricerca: Articlepeer review

5 Citazioni (Scopus)

Abstract

Triflusal is an antiplatelet drug related to aspirin, with different pharmacological properties and a lower haemorrhagic risk. We aimed at comparing their effects on platelet and endothelial activation in type 2 diabetes mellitus (T2DM).In a randomized, double-blind, parallel group study, we compared the effects of three daily regimens (300, 600, and 900 mg) of triflusal, and aspirin (100 mg/day) on urinary 11-dehydro-thromboxane (TX)B-2, index of in vivo platelet activation, ex vivo platelet function using the analyzer PFA-100, plasma von Willebrand factor (vWF), P-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and serum nitrite and nitrate (NO2- + NO3-) in 60 T2DM patients.Triflusal induced a dose-dependent reduction in 11-dehydro-TXB2 and a prolongation of closure time in the presence of collagen plus epinephrine (Coll/Epi-CT). The effects of the highest triflusal dose were not different from those of aspirin. The closure time in the presence of collagen Plus ADP (Coll/ADP-CT), ICAM-1, VCAM-1, and NO2- + NO3- were not modified either by triflusal or aspirin. Plasma P-selectin and vWF were reduced by triflusal but not by aspirin.In T2DM triflusal causes a profound inhibition of platelet TXA(2) biosynthesis in vivo, acting on different targets involved in the platelet-endothelial cell interactions
Lingua originaleEnglish
pagine (da-a)329-335
Numero di pagine7
RivistaATHEROSCLEROSIS
Volume183
Stato di pubblicazionePublished - 2005

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Entra nei temi di ricerca di 'Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus.'. Insieme formano una fingerprint unica.

Cita questo